Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma (Q44340720)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Mariano Esteban

5

object named as

Mariano Esteban

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

Fernando Abaitua

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Juan Ramón Rodríguez

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ana Garzón

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Dolores Rodríguez

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

7 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

11-20

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Functional diversity of helper T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Antigen presentation by MHC class I and its regulation by interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

The preparation and characteristics of highly purified radioactively labelled poxvirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Inhibition of Viral Replication by Interferon-γ-Induced Nitric Oxide Synthase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Quantification of antigen specific CD8+ T cells using an ELISPOT assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

The expanding universe of T-cell subsets: Th1, Th2 and more.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Commitment factors for T helper cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Th1 genetic adjuvants modulate immune responses in neonates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Generation and in vivo persistence of polarized Th1 and Th2 memory cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

Interferon-gamma: biology and role in pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIRUSRES.2005.08.008

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44340720&oldid=2109572714"